Donald Jensen to Proline
This is a "connection" page, showing publications Donald Jensen has written about Proline.
Connection Strength
1.384
-
The FDA, bridging data, and hepatitis C. Hepatology. 2013 Mar; 57(3):875-7.
Score: 0.459
-
A new era of hepatitis C therapy begins. N Engl J Med. 2011 Mar 31; 364(13):1272-4.
Score: 0.402
-
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.
Score: 0.179
-
Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49.
Score: 0.143
-
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
Score: 0.139
-
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
Score: 0.032
-
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14.
Score: 0.031